AbbVie Financials - Benzinga

AbbVie Inc

ABBVNYSE

Trade with Public

Trade with Public

$261.60

概要ニュース業績予想イベント目標株価財務センチメント株主構成配当比較オプション株式レポート

AbbVie Financials

AbbVie (ABBV) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Apogee Therapeutics Q2 EPS $(1.14) Misses $(1.05) Estimate

Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.05) by 8.57 percent. This is a 0.88 percent decrease over losses of $(1.13) per share

Benzinga Newsdesk

PRO
Conference Call: AbbVie Sees Q3 Adj EPS $3.84-$3.88 vs $3.84 Est; Sees Sales $17.200B vs $17.322B Est

AbbVie (NYSE:ABBV) is looking for Q3 Adj EPS of $3.84-$3.88 vs $3.84 analyst estimate. sees sales of $17.200 billion vs $17.322 billion analyst estimate.

Benzinga Newsdesk

AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat

AbbVie Inc. (NYSE: ABBV) shares are retreating Friday after trimming full-year adjusted EPS guidance below analyst targets.

Evette Mitkov

PRO
CORRECTION: AbbVie Lowers FY2026 Adj EPS Guidance from $13.91-$14.11 to $13.87-$14.07 vs $14.08 Est

AbbVie (NYSE:ABBV) lowers FY2026 Adj EPS guidance from $13.91-$14.11 to $13.87-$14.07 vs $14.08 analyst estimate..

Benzinga Newsdesk

PRO
AbbVie Q2 Adj. EPS $3.65 Beats $3.60 Estimate, Sales $16.990B Beat $16.765B Estimate

AbbVie (NYSE:ABBV) reported quarterly earnings of $3.65 per share which beat the analyst consensus estimate of $3.60 by 1.39 percent. This is a 22.9 percent increase over earnings of $2.97 per share from the same period

Benzinga Newsdesk

PRO
AbbVie Says Q2 2026 Includes $291M Bought IPR&D Expense, Impacting GAAP And Adj Diluted EPS By $0.17; Sees FY2026 Adj Diluted EPS At $13.91-$14.11 ; Sees Q2 2026 Adj Diluted EPS At $3.57-$3.61

Reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2026 are expected to include acquired IPR&D and milestones expense of $291 million on a pre-tax basis, representing an unfavorable

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved